Cure Pharmaceutical Holding Corp (OTCMKTS:CURR) Earns Cgmp Certification of NSF International for Dietary Supplements

Being able to develop, deliver, and possibly improve drug efficacy, safety, and patient experience is the mission for every pharmaceutical company. Having the right products is one thing, but it’s another thing altogether to access the key markets. Cure Pharmaceutical Holding Corp (OTCMKTS:CURR) knows it too well that having the correct certification is one of the key drivers to success, depending on your target market.

With that know-how, the company says it has earned NSF International, cGMP certification for its 25,000 square foot manufacturing facility. Thus it can now manufacture dietary supplements.

The issuance of the certification means the manufacturer complies with cGMP requirements listed in Section 8 of NSF/ANSI Standard 173. It also follows a comprehensive analysis of the facility and assurances from consumers, retailers, regulators, and suppliers that the company’s products meet the highest standards for safety, quality, and performance.

The Certification Confirms the High Standards the Company Apply To Its Management Processes

The NSF cGMP certification of manufacturing facilities is a rigorous and demanding process. It is carried out under very strict standards aimed at protecting public health. Once accomplished, it gives companies a wide scope of their target market for quality products. It is also a clear indication that the companies are using the right manufacturing processes.

To affirm this, CURE Pharmaceutical CEO, Rob Davidson says that the certification benefits both the company and the consumers.

“With the NSF-certified logo on wellness products developed and manufactured by CURE, consumers can be confident that our products meet strict standards for public health protection,” Davidson highlighted.

CURE Introduces Exclusive Licensing Relationships to Build Global Market Share

Europe is one of the world’s largest medical cannabis markets. This has pushed CURE to launch an exclusive licensing agreement with one of Europe’s leading pharmaceutical groups, ReLeaf Europe. The group tackles the largest market in the world for cannabis and has established a foothold in Holland.

The agreement outlines that CURE will give ReLeaf Europe exclusive access to its encapsulation technology for certain topical cannabis products in the Netherlands. The two companies share common values, according to the CEO of ReLeaf Europe, Jesse Kuijper.